ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

This large Phase 3 trial is testing whether a drug called inclisiran can reduce major heart problems like heart attacks and strokes in people who already have heart disease. About 17,000 participants are taking either inclisiran or a placebo, along with their usual cholesterol-lo…

This study follows 600 Belgian adults with atherosclerotic cardiovascular disease who are prescribed inclisiran, a cholesterol-lowering injection, alongside their usual medications. Researchers will measure how much LDL cholesterol drops and how many patients reach their target l…

This study compares two cholesterol-lowering strategies in adults aged 75 and older who have heart or blood vessel disease. One group aims for a very low LDL cholesterol target (below 55 mg/dL) using high-intensity statins, while the other receives standard moderate-intensity sta…

This large phase 3 study tests a new cholesterol-lowering injection called inclisiran in over 16,000 people who have already had a heart attack, stroke, or artery surgery. The goal is to see if it safely reduces the risk of future heart attacks, strokes, or the need for emergency…

This Phase 3 trial is testing an oral drug called MK-0616 (enlicitide decanoate) in about 14,550 people at high risk for heart problems. The drug aims to lower cholesterol and reduce the chance of major events like heart attacks, strokes, and emergency artery procedures. Particip…

This Phase 3 trial is testing whether a monthly injection of ziltivekimab can reduce the risk of heart attacks and strokes in 6,200 people who already have heart disease, chronic kidney disease, and signs of inflammation. Participants receive either the drug or a placebo for up t…

This study tests a daily pill (obicetrapib plus ezetimibe) to see if it can reduce fatty plaque buildup in the arteries of 300 adults with heart disease. Participants must already be on cholesterol-lowering therapy but still have high LDL cholesterol and measurable plaque. The tr…

This study follows 116 people who received an experimental gene-editing therapy for heart disease or high cholesterol. Researchers will monitor them for 15 years to track any side effects and how well the treatment controls cholesterol levels. The goal is to understand the long-t…

This study tests a drug called olpasiran in about 7,300 people with heart disease and high levels of a fatty particle called Lp(a). The goal is to see if olpasiran can lower the chance of heart attacks, urgent heart procedures, or death from heart disease compared to a placebo. P…

This study tests a drug called inclisiran in about 345 Asian patients who have heart disease or are at high risk and still have high LDL (bad) cholesterol despite taking statins. The goal is to see if inclisiran lowers LDL cholesterol more than a placebo over about 11 months, and…

This study tests inclisiran, a twice-yearly injection, to help people with heart disease or at high risk for it reach their LDL cholesterol goals. It focuses on groups often understudied, like women, Black, Hispanic, and rural patients. The trial enrolls 130 adults and measures w…

This large, phase 4 trial is testing whether berberine, a natural compound, can prevent heart disease and diabetes in over 2,000 high-risk adults in China. Participants take berberine or a placebo twice daily, plus receive lifestyle advice. The study tracks blood sugar and heart …

This observational study follows about 198 patients in Spain who are already taking inclisiran (Leqvio) for high cholesterol linked to heart disease or a genetic condition. Researchers will check if patients reach their LDL cholesterol goals after 6 and 12 months. The goal is to …

This study looks at two medicines, alirocumab and inclisiran, that help lower bad cholesterol (LDL-C) in people with heart disease. Researchers will use real-world data from about 124 patients to see which drug reduces cholesterol more over time. The goal is to understand how the…

This study aimed to see if telling patients and their doctors about calcium buildup in heart arteries (found on lung cancer scans) would lower the chance of death, heart attack, or stroke. It was designed for adults without known heart disease who had a lung scan showing signific…

This study was designed to see if a cholesterol-lowering drug called a PCSK9 inhibitor could also reduce inflammation in the arteries of people with heart disease. Researchers planned to use a special imaging scan to measure inflammation. The study was withdrawn before enrolling …